ArticleJournal of pharmaceutical health care and sciences2026
Clinical assessment of blood glucose responses to 300-mg dose of L-theanine, an amino acid unique to green tea, in a fixed-sequence, two-period trial.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundL-theanine (N-ethyl-γ-glutamine), an amino acid found in tea leaves and known for contributing to their umami taste, is widely marketed as a supplement for promoting relaxation. Recently, potential effects on blood glucose regulation have been reported. This study evaluated the effect of oral L-theanine intake on blood glucose levels using an oral glucose tolerance test (OGTT) in healthy adults.
methodsHealthy adult participants ingested 300 mg of L-theanine 15 min before the OGTT. Blood glucose levels were measured at 0 (baseline), 30, 60, 90 and 120 min after the start of the OGTT. A fixed-sequence, two-period trial was conducted: at Visit 1 (pre-intervention), the OGTT was performed without L-theanine, whereas at Visit 2 (intervention), the participants ingested 300 mg of L-theanine before undergoing the OGTT. In addition to blood samples, urine samples were collected whenever the participants felt the need to void and analyzed for glucose, sodium ions, and amino acids.
resultsThirty-nine healthy adults participated in the study. Although blood glucose levels tended to be lower at Visit 2 than at Visit 1, there was no statistically significant difference in the primary endpoint, defined as the difference between the peak glucose level and baseline. Thirty minutes after the start of the OGTT, corresponding to the time when serum L-theanine reached its peak, urinary glucose excretion tended to be higher and urinary sodium ions tended to be lower at Visit 2, although the difference was not statistically significant. Urinary excretion of glutamic acid, aspartic acid, and several other amino acids significantly increased during Visit 2. DISCUSSION: L-theanine may exert a glucose-lowering effect through previously reported mechanisms; however, the effect observed in this study was extremely small and unlikely to raise clinical concerns. Further research is required to clarify the potential effects of long-term L-theanine consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.